Controversies: Is Finasteride Safety Data Adequately Reported in Published Trials?
May 2015
in “
Hair transplant forum international
”
TLDR Finasteride safety data in trials may be underreported or misrepresented.
The document discussed the adequacy of safety data reporting in published trials of finasteride for androgenic alopecia. It referenced a meta-analysis published in JAMA Dermatology by Belknap et al., which examined adverse event reporting in these clinical trials. The analysis suggested that there were controversies regarding how well safety data was reported, indicating potential underreporting or misrepresentation of adverse effects associated with finasteride use. This raised concerns about the transparency and reliability of the safety information provided in these trials.